CER Daily Newsfeed

The Comparative Effectiveness Research Daily Newsfeed®, known for short as the CER Daily Newsfeed®, offers the latest news, research and related information on comparative effectiveness research, real-world data and evidence, value assessment and other important health care topics. 

News from Tuesday, September 26, 2023


NPC Evaluates ICER’s Revised 2023 Value Assessment Framework: A Missed Opportunity for Patients and the Field

(9/25, National Pharmaceutical Council: E.V.I.dently Today) comments “...Consistent with NPC’s comments, ICER did not lower its threshold range when stating its opinion on the value of treatments. However, ICER continues to threaten to put its thumb on the pricing scale of innovative treatments. Doing so signals a narrowly focused interpretation of a treatment’s value and can do more harm than good to patient access. ICER documented enhanced approaches to patient engagement. However, it remains to be seen whether these efforts will lead to more patient-focused inputs being incorporated into ICER’s analyses and results vs. being another box-checking exercise.” Full


ICER Finalizes Its Approach to Value Assessment. Industry Remains Dissatisfied

(9/26, Brian Reid, Cost Curve) comments “...The topline conclusion is that ICER’s approach, at its core, isn’t going to change that much...Industry had hoped for better. ‘Look, value assessment is not a rule, it is a tool comprised of both science and opinion,’ NPC’s John O’Brien said via email. ‘We're very concerned about the areas that weren't addressed because they have the potential to harm patients and do a disservice to those who've dedicated their lives to the scientific application of value methods.’” Full


Practice Points Developed for Treatment of Outpatient COVID-19

(9/26, HealthDay News) reports “...‘More research evaluating the efficacy, effectiveness, and comparative effectiveness, as well as harms, of pharmacologic and biologic treatments of COVID-19 in the outpatient setting is needed, particularly in the context of changing dominant severe acute respiratory syndrome coronavirus 2 variants and subvariants,’ the authors write.” Full


Advancing Value-Based Care: AMA, AHIP and NAACOS Team up to Launch New Playbook

(9/26, Dan Cook, Benefits Pro) reports “...[A] collaboration of three major organizations has launched a campaign to address the barriers that have so far clipped VBC’s wings. AHIP, the American Medical Association (AMA), and the National Association of ACOs (NAACOS) unveiled their barrier-busting strategy recently with the release of a playbook designed to work VBC adopters over and under the obstacles. The playbook–The Future of Value-Based Care and Payment–went public with the support of a half-hour webinar devoted to the first phase of implementation: data sharing.” Full

Press Releases

ICER Releases Draft Evidence Report on Treatment for Pulmonary Arterial Hypertension

(9/25, ICER Press Release) “The Institute for Clinical and Economic Review today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of sotatercept (Merck & Co) for pulmonary arterial hypertension...On October 5, 2023, as part of ICER’s Early Insights Webinar Series, ICER’s Chief Medical Officer, David Rind, MD will present the initial findings of this draft report.” Full


Medicare Advantage and Medicare Prescription Drug Programs to Remain Stable in 2024

(9/26, CMS Press Release) “...[M]ore than 1,500 Medicare Advantage plans will participate in the CMS Innovation Center’s Medicare Advantage Value-Based Insurance Design (VBID) Model in 2024, which will test the effect of offering person-centered innovative benefits that are critical to meeting health care needs and improving health equity to a projected 8.7 million people. The VBID Model expands access to additional supplemental benefits that can address a wide range of needs, such as food and nutrition benefits. The VBID Model offers plans the flexibility to target these benefits to people with chronic conditions or low incomes.” Full


COTA Announces New Data Platform to Accelerate Cancer Research and Advance Generative AI Models for Cancer Care

(9/26, COTA Press Release) “...‘Real-world data that tells a more complete story of a patient has accelerated our understanding of cancer and the development of lifesaving and life-extending therapies,’ said Miruna Sasu, CEO of COTA. ‘Generative AI has even more potential to advance treatment options for millions of people if we can build trusted large language models for oncology. That means first curating and validating data at a fundamentally different pace and scale. That’s what we are doing with Vista.’” Full


NICE Draft Guidance Recognises Potential of New Targeted Treatment for Type of Advanced Breast Cancer

(9/26, NICE Press Release) “NICE has today published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for treating advanced HER2-low breast cancer in adults. NICE’s independent appraisal committee has asked the company for more information ahead of its next meeting.” Full


Comparative Effectiveness and Safety of Drug Therapy for Chronic Urticaria: A Network Meta-Analysis and Risk-Benefit Assessment

Tian Qian, et al.

September 25, 2023, Expert Opinion on Drug Safety



The Future of Sustainable Value-Based Payment: Voluntary Best Practices to Advance Data Sharing




Sotatercept for Pulmonary Arterial Hypertension

September 25, 2023



Trustworthy Artificial Intelligence (TAI) for Patient-Centered Outcomes Research (PCOR)

September 26, 2023

Office of the Assistant Secretary for Planning and Evaluation